The prevalence and incidence of type 2 diabetes are progressively increasing because of a concomitant rise in the prevalence of obesity. Intentional weight loss in patients with type 2 diabetes has been associated with a 25% reduction in total mortality and a 28% reduction in cardiovascular disease and diabetes mortality (1). Weight gain is not only a risk factor for development of type 2 diabetes, but it is also the undesirable feature of several current antidiabetic treatments such as thiazolidinediones, sulfonylureas, and insulin, with an estimated 2-kg weight gain for every 1% decrease inHbA1c). Reasons for this include defensive snacking to treat or prevent hypoglycemia, decreased glucosuria, decreased basal metabolic rate, and expansion in adipose tissue and fluid retention.Recently, novel therapeutic agents were developed for the treatment of type 2 diabetes. Among these are the incretin based therapies, which include glucagon like peptide (GLP)-1 receptor agonists and inhibitors of the protease dipeptidyl peptidase (DPP)-4. Both classes of drugs use the antidiabetic properties of GLP-1, an incretin hormone that potentiates insulin secretion in a glucose-dependent manner.

Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes / Sesti, G. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - 11:Suppl. 3(2009), pp. 4-10. [10.1111/j.1463-1326.2009.01072.x]

Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes

SESTI G
Primo
Writing – Original Draft Preparation
2009

Abstract

The prevalence and incidence of type 2 diabetes are progressively increasing because of a concomitant rise in the prevalence of obesity. Intentional weight loss in patients with type 2 diabetes has been associated with a 25% reduction in total mortality and a 28% reduction in cardiovascular disease and diabetes mortality (1). Weight gain is not only a risk factor for development of type 2 diabetes, but it is also the undesirable feature of several current antidiabetic treatments such as thiazolidinediones, sulfonylureas, and insulin, with an estimated 2-kg weight gain for every 1% decrease inHbA1c). Reasons for this include defensive snacking to treat or prevent hypoglycemia, decreased glucosuria, decreased basal metabolic rate, and expansion in adipose tissue and fluid retention.Recently, novel therapeutic agents were developed for the treatment of type 2 diabetes. Among these are the incretin based therapies, which include glucagon like peptide (GLP)-1 receptor agonists and inhibitors of the protease dipeptidyl peptidase (DPP)-4. Both classes of drugs use the antidiabetic properties of GLP-1, an incretin hormone that potentiates insulin secretion in a glucose-dependent manner.
2009
type 2 diabetes; glp-1; obesity; incretin
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes / Sesti, G. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - 11:Suppl. 3(2009), pp. 4-10. [10.1111/j.1463-1326.2009.01072.x]
File allegati a questo prodotto
File Dimensione Formato  
Sesti_Harnessing-the weight-regulating_2009.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 246.06 kB
Formato Adobe PDF
246.06 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1312245
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact